Industry News
Biotechnology Industry News
Novartis is putting down $30…
Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new drug in the neurodegeneration space.
Another cell therapy biotech has…
Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. California CAR-T company Appia Bio has closed up shop, founding CEO JeenJoo “JJ” Kang, Ph.D., wrote in an Aug.
Eli Lilly reported that all three…
Eli Lilly reported that all three doses of its oral GLP-1 orforglipron helped patients who are obese or overweight with Type 2 diabetes achieve “significant” weight loss in a phase 3 trial. The drug also
Akeso is adding a pair of…
Akeso is adding a pair of late-stage wins to its scorecard in both ankylosing spondylitis and atopic dermatitis, while also teeing up a new drug submission for one of the candidates.
Amid a frozen-over IPO landscape,…
Amid a frozen-over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its modification of an ex-Sanofi drug.
After a nearly month-long delay,…
After a nearly month-long delay, the Food and Drug Administration has approved the investigational new drug application for Coya Therapeutics’ amyotrophic lateral sclerosis asset. With the FDA’s go-ahead, Coya plans to launch a multicenter phase
Arnatar Therapeutics has unveiled…
Arnatar Therapeutics has unveiled with $52 million in series A financing to bankroll new RNA-based therapies, including a lead candidate that takes aim at a rare genetic disease called Alagille syndrome.
AbbVie has written the next…
AbbVie has written the next chapter in its epic quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate from Gilgamesh Pharmaceuticals for up to $1.2 billion.
PDS Biotech has reported final…
PDS Biotech has reported final phase 2 data on PDS0101 in head and neck cancer, linking a combination of the immunotherapy and Keytruda to median overall survival of 39.3 months.
The Supreme Court is allowing the…
The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower court’s decision that required the National Institutes of Health to keep funding the terminated grants.
Arena BioWorks has laid off 30% of…
Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell Labs model to biotech.
Lighthouse Pharmaceuticals’ plan…
Lighthouse Pharmaceuticals’ plan to become a beacon of hope for Alzheimer’s disease patients has received almost $50 million in U.S. government support.
The Cleveland Clinic’s Nathan…
The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology medical affairs at Bristol Myers Squibb.
The FDA’s recent rebuff of…
The FDA’s recent rebuff of Replimune’s melanoma candidate has rippled across the industry, prompting one biotech to shutter a clinical trial evaluating a similar drug.
The FDA has accepted Stealth…
The FDA has accepted Stealth BioTherapeutics’ third new drug application for its ultrarare disease candidate, providing a planned decision date of Sept. 26.
Gilead has become the latest…
Gilead has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics.
Dynavax’s lofty ambition to…
Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase 1/2 study.
The FDA has freed Rocket…
The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight with its pivotal cardiomyopathy disease trial.
Xoma Royalty is ravenous for…
Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. Xoma is set to acquire Mural for $2.035 per share, for a total value of
The first half of 2025 was brutal…
The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several indications and silver linings exist, particularly for private companies.